[Evaluation of the Antianginal Efficacy of Ivabradine In Patients With Ischemic Heart Disease Complicated by Heart Failure].

Results of the multicenter open observational program NACHALO (evaluation of therapy in patients with combined coronary artery disease and heart failure as part of daily clinical practice), in which 569 doctors in 58 regions of the Russian Federation participated, were presented. The program included 2751 patients with ischemic heart disease, stable angina complicated by heart failure at the age from 25 to 94 years (mean age 62.6 ± 9.3 years). The follow-up period was 3 months, during which two visits were carried out--after 4 weeks and a final visit--12 weeks after the initiation of therapy. Despite treatment, angina attacks (mean 6.7 6.1 per week), increased blood pressure (average 145.1 ± 20.9/87.2 ± 1.8 mm Hg) and heart rate (average 85.8 ± 9.5 beats/min) were noted in patients before the inclusion in the program. The addition of ivabradine therapy resulted in a significant (p < 0.00001) reduction in heart rate to 73.2 ± 8.7 (at visit 1) and down to 65.2 ± 6.1 beats/min (at visit 2), the number of angina attacks per week to 3.8 (at visit 1) and 1.9 (at visit 2). There were significant (p < 0.00001) positive dynamics of the clinical wellness and the severity of symptoms in patients. Adverse effects that, according to doctors, were associated with the agent, were observed in only 0.15% of cases. Thus, in real clinical practice inhibitor of the if channels ivabradine has been shown to be highly effective in treatment of stable angina in patients with coronary artery disease complicated by heart failure.